# EDGAR Filing Document

**Accession Number:** 0001889791
**File Stem:** 0001493152-25-028448
**Filing Date:** 2025-12
**Character Count:** 4790
**Document Hash:** 7e2074bb29081fa89724da181b620e11
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-028448.hdr.sgml**: 20251219

**ACCESSION NUMBER**: 0001493152-25-028448

**CONFORMED SUBMISSION TYPE**: 8-A12B/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251219

**DATE AS OF CHANGE**: 20251219

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INNOCAN PHARMA Corp
- **CENTRAL INDEX KEY:** 0001889791
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-A12B/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42859
- **FILM NUMBER:** 251585094

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1015, 926 - 5 AVENUE SW
- **CITY:** CALGARY
- **PROVINCE COUNTRY:** Z4
- **ZIP:** T2P 0N7
- **BUSINESS PHONE:** 403-777-1519

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1015, 926 - 5 AVENUE SW
- **CITY:** CALGARY
- **PROVINCE COUNTRY:** Z4
- **ZIP:** T2P 0N7

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-A/A**

**Amendment No. 2**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES**

**PURSUANT TO SECTION 12(b) OR (g) OF**

**THE SECURITIES EXCHANGE ACT OF l934**

**INNOCAN PHARMA CORPORATION**

**(Exact name of Registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Canada** | **Not Applicable** |
| **(State of incorporation**<br> **or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| 1015, 926 – 5 Avenue SW<br> Calgary, Alberta, Canada<br> +1 (516) 210-4025 | T2P 0N7 |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Securities to be registered pursuant to Section 12(b) of the Act:**

---

| | |
|:---|:---|
| **Title of each class to be so registered** | **Name of each exchange on which each class is to be registered** |
| **Common Shares, no par value** | **NYSE American, LLC** |

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), please check the following box. ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), please check the following box. ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

**Securities Act registration statement file number to which this form relates:**

**333-288899**

**Securities to be registered pursuant to Section 12(g) of the Act:**

**None**

**(Title of Class)**

**EXPLANATORY NOTE**

This Amendment No. 2 to Form 8-A amends and restates in its entirety the Form 8-A filed with the Securities and Exchange Commission on September 22, 2025, as amended on December 16, 2025

**Item 1. Description of Registrant's Securities to be Registered.**

The description of (i) common shares, no par value, of Innocan Pharma Corporation (the "Registrant"), as included under the caption "Description of Share Capital" and (ii) the warrants of the Registrant, as included under the caption "Description of Securities we are Offering – Warrants Included in the Units", each in the prospectus forming a part of the Registration Statement on Form F-1 (Registration No. 333-288899) initially filed with the U.S. Securities and Exchange Commission on July 23, 2025, as amended (the "Registration Statement"), filed under the Securities Act of 1933, as amended (the "Securities Act"), is incorporated by reference herein. In addition, any description of such securities contained in a form of prospectus relating to the Registration Statement subsequently filed by the Registrant pursuant to Rule 424(b) under the Securities Act shall be deemed to be incorporated by reference herein.

**Item 2. Exhibits.**

No exhibits are required to be filed because no other securities of the Registrant are registered on The NYSE American, LLC and the securities registered by the Original Form 8-A are not registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Innocan Pharma Corporation** | **Innocan Pharma Corporation** |
| By: | */s/ Iris Bincovich* |
| Name: | Iris Bincovich |
| Title: | Chief Executive Officer |

---

Dated: December 19, 2025